Sutro Net Working Capital from 2010 to 2024

STRO Stock  USD 2.60  0.01  0.38%   
Sutro Biopharma Net Working Capital yearly trend continues to be very stable with very little volatility. Net Working Capital is likely to drop to about 220.4 M. During the period from 2010 to 2024, Sutro Biopharma Net Working Capital quarterly data regression pattern had sample variance of 18882.5 T and median of (6,327,000). View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
327.8 M
Current Value
220.4 M
Quarterly Volatility
137.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sutro Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sutro Biopharma's main balance sheet or income statement drivers, such as Interest Income of 12.7 M, Depreciation And Amortization of 7.3 M or Interest Expense of 24.9 M, as well as many indicators such as Price To Sales Ratio of 1.59, Dividend Yield of 0.0 or PTB Ratio of 0.93. Sutro financial statements analysis is a perfect complement when working with Sutro Biopharma Valuation or Volatility modules.
  
Check out the analysis of Sutro Biopharma Correlation against competitors.
To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.

Latest Sutro Biopharma's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Sutro Biopharma over the last few years. It is Sutro Biopharma's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sutro Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Sutro Net Working Capital Regression Statistics

Arithmetic Mean105,245,117
Geometric Mean32,785,602
Coefficient Of Variation130.57
Mean Deviation120,296,141
Median(6,327,000)
Standard Deviation137,413,588
Sample Variance18882.5T
Range354.9M
R-Value0.84
Mean Square Error5945T
R-Squared0.71
Significance0.000085
Slope25,847,776
Total Sum of Squares264354.9T

Sutro Net Working Capital History

2024220.4 M
2023327.8 M
2022286.6 M
2021176.8 M
2020348.6 M
201995.6 M
2018173.5 M

About Sutro Biopharma Financial Statements

Sutro Biopharma investors utilize fundamental indicators, such as Net Working Capital, to predict how Sutro Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Working Capital327.8 M220.4 M

Pair Trading with Sutro Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Sutro Stock

  0.8VALN Valneva SE ADRPairCorr

Moving against Sutro Stock

  0.42KZR Kezar Life SciencesPairCorr
  0.33RNXT RenovoRxPairCorr
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Sutro Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sutro Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sutro Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sutro Biopharma Stock:
Check out the analysis of Sutro Biopharma Correlation against competitors.
To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.55)
Revenue Per Share
2.253
Quarterly Revenue Growth
(0.50)
Return On Assets
(0.18)
Return On Equity
(1.11)
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.